Patient with RRMS according to 2024 McDonald's criteria.
Less than 10 years from disease onset.
Active RRMS (EDA) observed during the last 24 months: relapse and/or NELs and/or CELs as compared to a previous MRI performed within 24 months (± 3 months).
Current MET (IFN, GA, TE, fumarates) for less than 24 months.
Standard MRI follow-up scan performed less than 90 days before inclusion.
Clinically stable disease for at least 30 days.
Patients included in observational studies and cohorts (OFSEP, PROMISE …) will be eligible for inclusion in MoMo-NfL.
For women with reproductive potential: negative pregnancy test at the time of inclusion and use of an effective method to avoid pregnancy for the duration of the trial.
Patients able to adhere to the study visit schedule.
Patient must have signed and given the consent.
Patient affiliated or beneficiary of a health insurance plan.
You may not be if
Pregnant or breastfeeding woman.
Patient unable to perform brain and/or spinal cord MRI scans.
Patient not willing to perform monthly blood punctures.
Patient treated with HET (S1P agonists, natalizumab, ocrelizumab, ofatumumab, rituximab, alemtuzumab, cladribine, mitoxantrone).
Patient with a relapse within 6 months before inclusion.
Patient with CELs within 3 months before inclusion.
Patient with progressive MS.
Patient unable to sign the consent.
It is impossible to correctly inform the patient.
Patient already participating in therapeutic research or in an exclusion period. The exclusion period corresponds to five half-lives (t1/2) of the experimental drug.
Patient under judicial protection, or is an adult under guardianship.
Female patients who are pregnant or breastfeeding or of reproductive potential who are not willing to employ effective birth control for the duration of the trial.
